Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial

Bendamustine is a bifunctional alkylating agent with proven activity in myeloma. In this study 60 newly diagnosed myeloma patients were given bendamustine plus bortezomib and prednisone in a regimen consisting of one cycle of bortezomib twice weekly for 6 weeks (1.3 mg/m(2) on days 1, 4, 8, 11, 22,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Mateos, María-Victoria, Oriol, Albert, Rosiñol, Laura, de Arriba, Felipe, Puig, Noemí, Martín, Jesús, Martínez-López, Joaquín, Echeveste, María Asunción, Sarrá, Josep, Ocio, Enrique, Ramírez, Gemma, Martínez, Rafael, Palomera, Luis, Payer, Angel, Iglesias, Rebeca, de la Rubia, Javier, Alegre, Adrian, Chinea, Ana Isabel, Bladé, Joan, Lahuerta, Juan José, Miguel, Jesús-F. San
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2015
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5004426/
https://ncbi.nlm.nih.gov/pubmed/25911554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.124818
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados